Crispr Therapeutics (CRSP) Reaches New 12-Month High at $26.28

Crispr Therapeutics AG (NASDAQ:CRSP) hit a new 52-week high on Tuesday . The stock traded as high as $26.28 and last traded at $23.48, with a volume of 848300 shares traded. The stock had previously closed at $21.25.

A number of research firms recently commented on CRSP. Oppenheimer reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, December 21st. SunTrust Banks reissued a “hold” rating and set a $16.00 target price on shares of Crispr Therapeutics in a research report on Friday, November 10th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. Barclays reissued a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a research report on Friday, September 8th. Finally, Piper Jaffray Companies began coverage on shares of Crispr Therapeutics in a research report on Friday, December 22nd. They set an “overweight” rating for the company. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $22.38.

The stock has a market capitalization of $963.13, a price-to-earnings ratio of -17.79 and a beta of 4.64.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). The company had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The company’s quarterly revenue was up 54.2% on a year-over-year basis. During the same period in the prior year, the business posted ($2.77) EPS. equities research analysts predict that Crispr Therapeutics AG will post -2.46 EPS for the current fiscal year.

In other news, Director Thomas Woiwode sold 3,059 shares of the stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $20.29, for a total value of $62,067.11. Following the sale, the director now owns 4,959 shares in the company, valued at $100,618.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tyler Dylan-Hyde sold 15,000 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $18.90, for a total transaction of $283,500.00. Following the completion of the sale, the insider now owns 130,204 shares in the company, valued at approximately $2,460,855.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,968,713 shares of company stock valued at $37,497,005. Corporate insiders own 39.98% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Hershey Trust Co. acquired a new stake in shares of Crispr Therapeutics in the third quarter worth $768,000. Tiff Advisory Services Inc. acquired a new stake in Crispr Therapeutics during the third quarter valued at $505,000. Adams Street Partners LLC acquired a new stake in Crispr Therapeutics during the third quarter valued at $1,019,000. Granahan Investment Management Inc. MA grew its position in Crispr Therapeutics by 51.7% during the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after buying an additional 89,839 shares during the period. Finally, Allianz Asset Management GmbH acquired a new stake in Crispr Therapeutics during the third quarter valued at $2,384,000. Hedge funds and other institutional investors own 24.52% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Crispr Therapeutics (CRSP) Reaches New 12-Month High at $26.28” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2018/01/02/crispr-therapeutics-crsp-reaches-new-12-month-high-at-26-28.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply